Sangamo Therapeutics
Price & Volume
Stats
See more52W Range | $0.34-$1.06 |
Market Cap | $143M |
Shares Short | 24M |
Financials
See moreRevenue (12 Mos) | $32.8M |
Revenue Growth (YoY) | -98.8% |
Gross Profit (12 Mos) | -$72M |
Diluted EPS | -$0.45 |
News
See moreYahoo Finance • 21 days ago
Sangamo plunges after pricing stock offering; principal financial officer exits
Yahoo Finance • 3 months ago
Hemophilia A Market to Exhibit Growth at a CAGR of 2.9% During the Forecast Period (2025-2034) Owing to the Rising Hemophilia Prevalence, Strong Uptake of New Drugs, and Emergence of High-cost Gene Therapies | DelveInsight
Yahoo Finance • 3 months ago
Sangamo rises as FDA grants Fast Track status to neuropathic pain asset
Yahoo Finance • 3 months ago
Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy
About
CEO | Dr. Alexander D. Macrae Ch.B, M.B., MRCP, Ph.D. |
Address | 501 Canal Blvd, Richmond, CA, United States, 94804 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 183 |
